Table 1.
Demographic characteristics, clinical manifestations and laboratory findings for patients with CAMP by age group.
| <2 y | 2–5 y | 6–9 y | 10–13 y | Total | P | |
|---|---|---|---|---|---|---|
| n = 12 (7.4%) | n = 70 (43.2%) | n = 46 (28.4%) | n = 34 (21%) | n = 162 (100%) | ||
| Demographic data | ||||||
| Positivity rate | 8.6% | 21.5% | 46.9% | 69.4% | 26.5% | <.001 |
| Sex (female) | 3 (25.0%) | 35 (41.7%) | 27 (32.1%) | 19 (55.9) | 84 (51.9%) | NS |
| Recurrent Wheezing* | 8 (66.7%) | 29 (41.4%) | 12 (26.1%) | 4 (14.8%) | 53 (32.7%) | .001 |
| Treatment | ||||||
| Empiric macrolide** | 2 (16.7%) | 17 (24.3%) | 15 (32.6%) | 10 (29.4%) | 44 (28.2%) | NS |
| Empiric β-lactam** | 8 (66.7%) | 22 (31.4%) | 12 (26.1%) | 7 (20.6%) | 49 (30.2%) | .024 |
| Empiric β-lactam+macrolide | 1 (8.3%) | 30 (42.9%) | 19 (41.3%) | 17 (50.0%) | 67 (41.4%) | NS |
| Systemic corticosteroids | 4 (33.3%) | 12 (17.1%) | 1 (2.2%) | 1 (2.9%) | 18 (11.1%) | .002 |
| Oxygen therapy | 3 (25.0%) | 17 (24.3%) | 2 (4.3%) | 1 (2.9%) | 23 (14.2%) | .003 |
| Admission | 9 (75.0%) | 35 (50.7%) | 13 (20.3%) | 7 (10.9%) | 64 (39.8%) | .001 |
| Length of stay | 5 (3–6.7) | 3 (1.5–5.0) | 3 (2.0–3.5) | 2 (1.0–4.0) | 3 (2.0–5.0) | NS |
| Manifestations | ||||||
| Pleural effusion | 1 (8.3%) | 11 (15.7%) | 7 (15.2%) | 3 (8.8%) | 22 (13.6%) | NS |
| Fever (°C) | 38.5 (38.0–39.0) | 38.9 (38.5–39.2) | 39 (38.4–39.5) | 39.5 (39–39.7) | 39 (38.5–39.5) | .001 |
| Duration of fever (hours) | 84 (33–120) | 96 (39–144) | 96 (48–144) | 144 (96–168) | 96 (48–144) | .01 |
| Laboratory | ||||||
| Leucocyte count (cells/μL) | 11 550 (9500–16 775) | 11 200 (9525–13950) | 9450 (7650–12 250) | 8300 (7000–9600) | 10 200 (8000–12 900) | .005 |
| Neutrophil count (cells/μL) | 6200 (2600–10 150) | 7900 (5225–11 725) | 6150 (4500–9700) | 5600 (4600–7000) | 6400 (4850–9950) | NS |
| Lymphocyte count (cells/μL) | 4800 (3625–5125) | 2300 (1625–3200) | 1850 (1500–2100) | 1500 (1100–1900) | 2000 (1450–2950) | <.001 |
| CRP (mg/dL) | 2.1 (1.3–3.9) | 3.4 (1.5–6.1) | 2.9 (1.6–6.1) | 3.2 (1.9–7) | 3 (1.5–6.0) | NS |
| PCT (ng/mL) | 0.7 (0.1–1.4) | 0.1 (0.1–0.1) | 0.1 (0.1–0.4) | 1.2 (0.0–2.4) | 0.1 (0.1–0.4) | NS |
CRP, C-reactive protein; NS, not significant; PCT, procalcitonin. Statistically significant differences are presented in boldface. Data expressed as absolute frequency and percentage or median and interquartile range.
*
Wheezing requiring bronchodilator therapy.
**
Prescription of macrolide or beta-lactam antibiotic as monotherapy.